ARS Pharmaceuticals Says CHMP Of European Medicines Agency Adopted Positive Opinion On Application For Marketing Authorization For EURneffy (Adrenaline Nasal Spray)
Portfolio Pulse from Benzinga Newsdesk
ARS Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion on the marketing authorization application for EURneffy, an adrenaline nasal spray. The CHMP recommended market authorization in the EU for the emergency treatment of allergic reactions (anaphylaxis). The formal marketing authorization process by the European Commission is expected to occur in Q3 2024.
June 28, 2024 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ARS Pharmaceuticals received a positive opinion from the CHMP for EURneffy, an adrenaline nasal spray for anaphylaxis. The formal marketing authorization by the European Commission is expected in Q3 2024.
The positive opinion from the CHMP is a significant step towards obtaining formal marketing authorization in the EU. This development is likely to boost investor confidence and positively impact the stock price of ARS Pharmaceuticals in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100